StreetInsider.com News Articles

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- These companies are stepping into the market spotlight with very different catalysts: NeOnc (NASDAQ:NTHI) is drawing Wall Street attention around its brain-cancer pipeline and a $20 price target; Profusa (NASDAQ:PFSA) is advancing the regulatory path for its Lumee Oxygen Platform; Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) is expanding into blockchain-powered ecosystem finance through its MindWave Innovations subsidiary; and Greenland Energy Company (NASDAQ:GLND) has extended the timeline for its Jameson Land exploration program in East Greenland.

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

Here’s What Investors Are Watching, Including $20 Price Target Bombshell

Thu, 24 Sep 2026 11:43:32 -0400

NeOnc Technologies Holdings: Wall Street Puts $20 Target on the Brain-Cancer Story

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

Thu, 24 Sep 2026 10:20:53 -0400

DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-cancer pipeline. Roth Capital analyst Jonathan Aschoff initiated coverage, according to a report published September 24.

The timing is notable. NeOnc is no longer simply pitching an early-stage concept: the company has recently reported clinical data, raised fresh capital and is positioning its lead programs for potentially pivotal development.

The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

Thu, 24 Sep 2026 10:20:53 -0400

The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in recurrent

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

Thu, 24 Sep 2026 10:20:00 -0400

The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in

NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

Thu, 24 Sep 2026 10:20:00 -0400

The most immediate story is NEO100. In August, NeOnc reported topline Phase 2a results in

Roth/MKM Starts NeOnc Technologies (NTHI) at Buy

Thu, 24 Sep 2026 03:11:06 -0400

Roth/MKM analyst Jonathan Aschoff initiates coverage on NeOnc Technologies (NASDAQ: NTHI) with a Buy rating and a price target of $20.00.

The analyst comments: “We initiate coverage of NTHI with a Buy rating and $20 12-month price target (DCF analysis uses 20% discount rate, 5x multiple of our projected $667M 2033 operating income). We project NEO100 and NEO212 to launch in 2029 and 2030, respectively. Pro forma cash of $9.9M funds operations through 2026. NTHI intends to develop NEO100 and NEO212 in recurrent grade 4 astrocytoma, and NEO212 in recurrent GBM and brain metastases, with pivotal trials potentially to start by

Roth/MKM Starts NeOnc Technologies (NTHI) at Buy

Thu, 24 Sep 2026 03:11:06 -0400

Roth/MKM analyst Jonathan Aschoff initiates coverage on NeOnc Technologies (NASDAQ: NTHI) with a Buy rating and a price target of $20.00.

NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier

Tue, 22 Sep 2026 14:52:00 -0400

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisticated era.

However, one of the field’s biggest problems remains stubbornly simple: getting effective therapy to the tumor while protecting the brain from additional damage. A July 2026 review in Science Translational Medicine described glioblastoma as remaining one of the most aggressive adult brain cancers, with survival still largely unchanged despite advances in molecular diagnostics and supportive care. At the same time, researchers are pursuing an

NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier

Tue, 22 Sep 2026 14:52:00 -0400

Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals